HOME >> MEDICINE >> NEWS
New therapeutic targets for neurodegenerative diseases

nder certain conditions, i.e. sensory symptoms, motor symptoms, etc. and that can be induced in these animals. And they are examining if these substances that have proved to be interesting with the in vitro cells are also efficacious in these experimental models of the diseases.

Moreover, over the past few years they have had the opportunity to study samples of brains of patients who have died of some neurodegenerative illness, such as, for example, multiple sclerosis. The illnesses leaves a mark in these samples and, although the brain has been at a terminal stage of the illness, they can investigate to see if there are signs of alterations to the molecules similar to those observed in the experiments, both with cells and with the animals. In this way it can be determined if the molecular targets discovered experimentally are relevant or not to the neurodegenerative processes and, if they are, develop pharmaceutical medicines that can neutralise these processes or the elements that enable them to progress, the goal being to halt the process of death.

In collaboration with neurologists they have also been able to access biological samples of patients who have given their consent and donated them to research. Biological samples such as, fundamentally, blood, given that changes in blood plasma that may indicate alterations at the brain level can be identified.

In search of biological samples

All this is a dynamic process that enables clues to be found and which are, in some cases, relevant for developing pharmaceutical drugs that can halt, or at least slow down, the course of a neurodegenerative illness. Apart from finding these molecules or targets that interact with pharmaceutical medicines, in order to stop the process of progressive deterioration, substances that favour the survival of the neurones and oligodendrocytes are also sought; substances such as, for example, antioxidants, given that, in many of
'"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
10-May-2007


Page: 1 2 3

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. OCT1 required for therapeutic effects of diabetes drug Metformin
3. NeuroRx changes name to Neurotherapeutics
4. Olive Leaf report documents promising therapeutic interventions for 9-11 workers
5. T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
6. Cerebrospinal fluid used to deliver therapeutics for Lou Gehrigs disease to brain
7. University to develop new therapeutics for cancer
8. Exubera: So far no evidence available of an additional therapeutic benefit
9. Nano-particles effective in killing cancer with one-two punch of chemotherapeutics
10. Researchers identify target for therapeutic drugs to fight most common adult brain cancer
11. Cedars-Sinai researchers demonstrate a new way to switch therapeutic genes on and off

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New therapeutic targets for neurodegenerative diseases

(Date:8/30/2015)... West Hempstead, NY (PRWEB) , ... August 31, ... ... system installer Total Security Integrated Systems announces specific strategies to help assisted living ... well as their grounds from break-ins and theft. According to security experts at ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... joined the company as the new Global Communications Director for InHealth Media. ... experience having spent the last 16 years doing on-air television, producing shows, on ...
(Date:8/30/2015)... Rosa, CA (PRWEB) , ... August 30, 2015 ... ... Intensity Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has ... – introduced this summer at the treatment center in Puerto Vallarta, Mexico. , ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... of two inventors from Miller Place, N.Y. "I specialize in manual therapy, and ... In addition, it can be used for additional muscle dysfunction throughout the body." ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Next weekend is ... summer (which astronomically, officially ends on September 22nd this year). For IT security personnel, ... hangovers linger on which could prove far more costly than a simple headache. , ...
Breaking Medicine News(10 mins):Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 2Health News:Total Security Announces Security Systems Tips for New York Assisted Living Facilities and Nursing Homes 3Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
Cached News: